(Kansas City, MO.) - On November 20, 2002 the New England Journal of Medicine published a report co-authored by Dr. Matthew Callister, M.D., a radiation oncologist on the medical staff of The Cancer Institute.
The article highlights a major discovery that could help doctors more accurately decide which breast cancer patients need more aggressive treatment and which can forego routine chemotherapy."This discovery is a major milestone for Dr. Callister and The Cancer Institute," remarked Doug Lawson, president of The Cancer Institute.
With breakthrough research such as this, and physicians like Dr. Callister
, we can truly improve the quality of cancer care not only locally but across the nation."The report that Callister co-authored with Dr. Khandan Keyomarsi, Ph.D., associate professor in experimental radiation oncology at M.D.
"This study is important for two reasons," remarked Callister
."First, using cyclin E, we may be able to determine a breast cancer patients prognosis with remarkably greater accuracy.More importantly, this molecule has the strong potential to establish which patients need to undergo treatment such as chemotherapy or radiation, as well as those patients who do not."
Prior to coming to Kansas City, Dr. Callister
initiated a confirmatory study of new patients at M.D.Anderson Cancer Center
in Houston, TX.
This study will likely provide crucial information regarding which patients need further treatment for cancer after surgery and who does not, continued Callister
.Hopefully, more women will be spared unnecessary treatment, while those with a high level of cyclin E normality can be identified for more aggressive cancer therapy.Callister holds a degree in Russian from Brigham Young University and received his medical degree from Duke University.He
internship at Mayo Clinic in Scottsdale.Prior to working with The Cancer Institute, Callister specialized in radiation oncology at M.D.Anderson where he researched the detection of cyclin E in new breast cancer patients.
"Working on this study has been a tremendously rewarding experience," stated Callister